Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

LivaNova Q3 2026 Results: Net Income $34.3M, Up 28.0% YoY

LivaNova PLC reported net revenue of $1.15 billion for the nine months ended September 30, 2026, a significant increase from $1.03 billion in the prior year period. The company swung to a net income of $165.2 million compared to a net loss of $273.4 million in 2025, primarily due to the absence of the large SNIA environmental liability expense recorded in the previous year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue393.1357.8
Gross profit265.1244.9
Profit before tax46.833.9
Net income34.326.8
EPS (diluted, $ a share)$0.11$0.49

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+28.0%
Revenue, year on year+9.9%
Gross margin67.4%
Operating margin7.2%
Source

10-Q filed with the SEC, NASDAQ: LIVN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

LivaNova PLC: key numbers

Share price
$92.44Close, Nov 16
Market cap
$5.09B
Shares outstanding
55.09MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from LivaNova PLC

All →
5:02 PM ET Form 4
Insider Selling

LivaNova CFO Alex Shvartsburg Sells $227K of Stock

Alex Shvartsburg, CFO, sold 2,500 shares of LivaNova PLC at $90.91 a share, worth $227K in total on Nov 12, 2026. Shares held after the trade: 42,147 (-5.6%).

Value
$227K
Shares
2,500
Price
$90.91
Role
CFO
Holding change
-5.6%
Trade date
Nov 12, 2026
6:04 AM ET 8-K
Financial Results

LivaNova Financial Results

LivaNova reported 9.9% revenue growth for the third quarter of 2026, driven by strong demand for its Cardiopulmonary and Epilepsy technologies. The company raised its full-year 2026 constant-currency revenue growth guidance to 9-10% and increased its adjusted diluted EPS outlook. Key operational milestones included the launch of a new oxygenator manufacturing line and the establishment of new CPT codes for its sleep apnea therapy.

Term
Q3 2026

“Our team continues to deliver robust revenue growth driven by commercial execution and healthy global demand for our Cardiopulmonary and Epilepsy technologies. We also made meaningful progress against key milestones, positioning us to address significant market demand while expanding patient access to care.”

Vladimir Makatsaria, Chief Executive Officer of LivaNova
4:24 PM ET Form 4
Insider Selling

LivaNova Insider Francesco Bianchi Sells $273K of Stock

Francesco Bianchi sold 3,500 shares of LivaNova PLC at $78.01 a share, worth $273K in total on Sep 10, 2026. Shares held after the trade: 4,434 (-44.1%).

Value
$273K
Shares
3,500
Price
$78.01
Holding change
-44.1%
Trade date
Sep 10, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.